Erasca, Inc. Investing Cash Flow
Erasca, Inc. (ERAS) reported Investing Cash Flow of -$224.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Erasca, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $19.49M, a 23.80% increase year-over-year.
- Erasca, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$243.83M, a 811.60% decline year-over-year.
- Erasca, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $24.71M, a 9.26% increase year-over-year.
- Erasca, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $25.70M.
- Erasca, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $100.42M.
- Erasca, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$156.62M.
- Erasca, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$91.22M.
- Erasca, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$71.08M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$224.34M 10-Q · filed 2026-08-11 | -$199.63M derived: sum of 3 quarters · filed 2026-08-11 | -$173.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$243.83M 10-Q · filed 2026-05-11 | -$219.12M derived: sum of 2 quarters · filed 2026-05-11 | -$193.41M derived: sum of 3 quarters · filed 2026-05-11 | -$177.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $24.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $50.41M derived: sum of 2 quarters · filed 2026-03-12 | $66.16M derived: sum of 3 quarters · filed 2026-08-11 | $100.42M 10-K · filed 2026-03-12 |
| 2025-09-30 | $25.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $41.45M derived: sum of 2 quarters · filed 2026-08-11 | $75.71M 10-Q · filed 2025-11-12 | $98.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $15.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $50.01M 10-Q · filed 2026-08-11 | $72.63M derived: sum of 3 quarters · filed 2026-08-11 | -$29.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $34.27M 10-Q · filed 2026-05-11 | $56.88M derived: sum of 2 quarters · filed 2026-05-11 | -$45.71M derived: sum of 3 quarters · filed 2026-05-11 | -$132.32M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $22.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$79.98M derived: sum of 2 quarters · filed 2026-03-12 | -$166.59M derived: sum of 3 quarters · filed 2026-03-12 | -$156.62M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$102.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$189.20M derived: sum of 2 quarters · filed 2025-11-12 | -$179.23M 10-Q · filed 2025-11-12 | -$174.69M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$86.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$76.64M 10-Q · filed 2025-08-12 | -$72.09M derived: sum of 3 quarters · filed 2025-08-12 | -$73.91M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $9.97M 10-Q · filed 2025-05-13 | $14.52M derived: sum of 2 quarters · filed 2025-05-13 | $12.70M derived: sum of 3 quarters · filed 2025-05-13 | -$95.96M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $2.73M derived: sum of 2 quarters · filed 2025-03-20 | -$105.93M derived: sum of 3 quarters · filed 2025-03-20 | -$91.22M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$110.48M derived: sum of 2 quarters · filed 2024-11-12 | -$95.77M 10-Q · filed 2024-11-12 | -$100.63M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$108.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$93.95M 10-Q · filed 2024-08-12 | -$98.82M derived: sum of 3 quarters · filed 2024-08-12 | -$154.05M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $14.71M 10-Q · filed 2024-05-08 | $9.85M derived: sum of 2 quarters · filed 2024-05-08 | -$45.38M derived: sum of 3 quarters · filed 2024-05-08 | -$54.57M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$60.10M derived: sum of 2 quarters · filed 2024-03-27 | -$69.29M derived: sum of 3 quarters · filed 2024-03-27 | -$71.08M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$55.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$64.42M derived: sum of 2 quarters · filed 2023-11-09 | -$66.21M 10-Q · filed 2023-11-09 | -$130.16M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$9.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$10.98M 10-Q · filed 2023-08-10 | -$74.93M derived: sum of 3 quarters · filed 2023-08-10 | -$79.87M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$1.79M 10-Q · filed 2023-05-15 | -$65.74M derived: sum of 2 quarters · filed 2023-05-15 | -$70.68M derived: sum of 3 quarters · filed 2023-05-15 | -$66.22M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$63.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$68.89M derived: sum of 2 quarters · filed 2023-03-23 | -$64.43M derived: sum of 3 quarters · filed 2023-03-23 | -$64.59M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$4.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$479.00K derived: sum of 2 quarters · filed 2022-11-09 | -$641.00K 10-Q · filed 2022-11-09 | $15.92M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $4.30M 10-Q · filed 2022-08-11 | $20.86M derived: sum of 3 quarters · filed 2022-08-11 | -$28.28M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$162.00K 10-Q · filed 2022-05-12 | $16.40M derived: sum of 2 quarters · filed 2022-05-12 | -$32.74M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $16.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$32.58M derived: sum of 2 quarters · filed 2022-03-24 | -$71.20M 10-K · filed 2022-03-24 | |
| 2020-09-30 | -$49.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$87.77M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$38.62M 10-Q · filed 2021-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |